DBL Pharma Inc. ends the year in USA with a Big Success
One of the top business Conglomerates of Bangladesh; DBL Group’s registered new initiative in USA – DBL Pharma Inc. ended the year with a notable success in USA. According to a recently released report by IQVA (previously known as IMS); in the methocarbamol generic tablet market of USA, with a share of 14.20%, DBL Pharma Inc. is in the 2nd position among 13 companies. The first position is being held by Indian company Granules Pharma’s partner company in USA.
Methocarbamol is a widely used medicine in USA for muscle pain. After the expiration of the patent propriety of the first marketer of this medicine; mostly the Indian generic medicine companies started occupying the market share. By the end of 2018; DBL group and Beximco Pharma of Bangladesh got approval of US FDA to market this medicine in USA.
DBL Group is investing in Pharmaceutical industry hand in hand with their success in Export based RMG and Ceramics business. With an investment of taka 700 crore and with the standard of US FDA; DBL Pharmaceuticals’ factory in Kashimpur, Gazipur will start producing medicines for Bangladesh market by the end of this year. In this factory consisting almost 10 Acres of land; European machineries are being set up for making Tablets, Capsules, Syrup, Injection, Inhaler along with all other types of medicines. Along with that, DBL also purchased production and quality control technology and machineries of Cream and Ointment of recently announced closed factory GlaxoSmithKline (GSK) Bangladesh Ltd.’s factory in Chattogram. As a result, DBL Pharma would be able to produce and serve the patients with the substitutes of Betnovate, Bactroban and other relevant medicines with the same quality control mechanisms using the same facility and technology that was being used by GSK.
Before this; in the first quarter of 2019 DBL Pharma Inc. started marketing in USA after purchasing propriety of 2 generic medicines of US FDA approved Methocarbamol doing contract manufacturing. DBL started with a surprise; as the 3rd Bangladeshi initiative among the medicine marketers in USA. DBL Pharma is hopeful to export to the developed countries along with USA after the production is active in the Kashimpur factory.
DBL Group’s Managing Director, Mr. M.A. Jabbar attends panel discussion on ‘The Sustainable Development of Apparel Export: Priorities and Way Forward’
DBL Group wins 3 Gold Awards at the International Convention on Quality Control Circles (ICQCC) 2017
South Avenue Tower, House # 50 (6th Floor), Road # 03, 7 Gulshan Avenue, Dhaka 1212, Bangladesh